Speaker(s): 

Travis Tayor, MD, Geisinger - has nothing to disclose.

Learning Objectives:

• Review/appraise information on white matter disease--such as effect on cognition. Examine clinical trial data from the recently published ETLAS-2 trial regarding potential treatment for reducing white matter disease/changes

Follow up questions:

1. What may have lead to the higher dropout of female patients to males?
2. Was there any evidence of a trend toward reduction in white matter hyperintensities on MRI Brain with Tadalafil?
3. Can we conclude anything from the article on potential benefit in terms of other agents/treatment options that may aid to reducing white matter hyperintensities?

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Anthony Noto, MD, David Ermak, DO, Lisa Wasko, BSN, RN, SCRN have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None